Drugs / cDNA Donor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02695160 | Nov 2016 → Apr 2021 | hemophilia B | Sangamo Therapeutics | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cDNA Donor | “Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.” NCT02695160 ↗ |
| Action | Restore | “placement of a corrective copy of the Factor IX transgene into the genome” NCT02695160 ↗ |
| Target | F9 | “SB-FIX is intended to function by placement of a corrective copy of the Factor IX transgene into the genome of the subject's own hepatocytes” NCT02695160 ↗ |